Saudi Arabia Next Generation Sequencing Market to Reach $50 Million by 2031
Meticulous Research®—a
leading global market research company, published a research report titled ‘Saudi
Arabia Next Generation Sequencing (NGS) Market Size, Share, Forecast, &
Trends Analysis by Offering (Sample Preparation (DNA Extraction, Library
Preparation), Instruments) Type (SMRT, DNB) Application (Clinical, Research)
End User–Forecast to 2031. According to this latest publication from Meticulous
Research®, the Saudi Arabia NGS market is expected to reach $50.0
million by 2031, at a CAGR of 10.1% from 2024 to 2031.
The growth of this
market is driven by the rising number of cancer cases, increasing
pharmaceutical R&D expenditures, and the surge in genome mapping programs
are factors driving the growth of the Saudi Arabia NGS market. However, the
high costs of NGS systems and consumables, data confidentiality concerns, the
availability of alternative technologies, the low chances of identifying
positive, actionable biomarkers, and ethical & legal issues related to
NGS-based diagnosis restrain the growth of this market
In addition,
increasing adoption of NGS tools among hospitals and clinical laboratories and
government initiatives supporting large-scale genomic sequencing projects are
expected to offer growth opportunities for market players. However, the
shortage of skilled professionals, issues related to data storage, handling,
interpretation, and confidentiality, and concerns about regulatory standards
and standardization in diagnostic testing are some of the challenges impacting
the market's growth.
Key Players:
Some of the key
players operating in Saudi Arabia NGS market are Illumina, Inc. (U.S.), Thermo
Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland),
Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc.
(U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation
(U.S.), Oxford Nanopore Technologies Plc. (U.K.), Beijing Genomics Institute
(BGI) (China), Bio-Rad Laboratories, Inc. (U.S.), and 10x Genomics, Inc.
(U.S.).
How Vision 2031 Is
Shaping NGS Adoption:
Saudi Arabia’s Vision
2031 isn’t just a policy document—it’s a comprehensive roadmap for the nation’s
future. In healthcare, the vision is clear: build a world-class system that
leverages the latest in medical science and technology. NGS fits perfectly into
this picture.
Under Vision 2031,
there’s a strong push for personalized medicine, where treatments are tailored
to each patient’s genetic profile. The government is investing heavily in
healthcare infrastructure, research, and public-private partnerships. This
means more funding for hospitals, research centres, and biotech companies to
adopt and implement NGS technologies.
NGS is already making
a difference in areas like cancer diagnosis, rare genetic disorders, and
infectious disease tracking. With Vision 2031’s backing, we can expect to see
even broader adoption of NGS in routine clinical practice, research, and even
public health initiatives. The ultimate goal? Better patient outcomes, more
efficient healthcare delivery, and a stronger, knowledge-based economy.
Main Drivers
Fueling NGS Market Growth in Saudi Arabia:
Rising Cancer
Incidence: Cancer remains a leading cause of death in Saudi Arabia, with cases
projected to rise from 28,113 in 2022 to 39,900 by 2030. NGS is
increasingly adopted in oncology for early detection, therapy selection, and
monitoring drug resistance, making it indispensable in modern cancer care.
Expanding Clinical
Applications: Beyond oncology, NGS is gaining traction in reproductive health,
Mendelian and complex disorders, and infectious disease diagnostics. The
ability to simultaneously analyse hundreds of genes or entire genomes enables
more accurate and comprehensive diagnoses.
Pharmaceutical &
Biotech Sector Growth: The government’s biotechnology initiatives are fostering
local R&D, leading to increased demand for NGS in drug discovery,
translational research, and clinical trials. Pharmaceutical and biotechnology
companies are expected to register the highest CAGR among end users during the
forecast period.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6002
Technological
Advancements Shaping the NGS Industry:
Portable Sequencing
Devices: The development of handheld, nanopore-based sequencers has made
genetic testing more affordable, faster, and accessible—even outside
traditional laboratory settings. These devices can sequence entire genomes for
less than $1,000 and are being used for real-time disease characterization and
population genomics.
Targeted Genome
Sequencing: This technology, which offers low cost, quick results, and
straightforward data analysis, is now the most widely adopted sequencing type
in Saudi Arabia. It is especially valuable for identifying somatic mutations in
cancer and other complex diseases.
Advances in
Consumables and Reagents: Ongoing improvements in reagents, kits, and target
enrichment protocols are driving the largest market segment—consumables—which
accounted for 62.6% of the market share in 2024 and is projected to reach $50
million by 2031
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment